Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03624231
Title Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD)
Acronym DURTRE-RAD
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Ulrich Keilholz
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Additional content available in CKB BOOST